Abstract:Background Predicting the recurrence risk of bladder cancer is crucial for the individualized clinical treatment of patients with bladder cancer. Objective To explore the radiomics based on multiphase CT images combined with clinical risk factors, and to further construct a radiomics-clinical model to predict the recurrence risk of bladder cancer within 2 years after surgery. Methods Patients with bladder cancer who underwent surgical treatment at the First Affiliated Hospital of Soochow University from January 2016 to December 2019 were retrospectively included and followed up to record the disease recurrence. A total of 183 patients were included in the study, and they were randomly divided into training group and validation group in a ratio of 7: 3. The three basic models which are plain scan, corticomedullary phase, and nephrographic phase as well as two combination models, namely, corticomedullary phase + nephrographic phase and plain scan + corticomedullary phase + nephrographic phase, were built with the logistic regression algorithm, and we selected the model with higher performance and calculated the Rad-score (radiomics score) of each patient. The clinical risk factors and Rad-score were screened by Cox univariate and multivariate proportional hazard models in turn to obtain the independent risk factors, then the radiomics-clinical model was constructed, and their performance was evaluated. Results Of the 183 patients included, 128 patients constituted the training group and 55 patients constituted the validation group. In terms of the radiomics-clinical model constructed by three independent risk factors—number of tumors, tumor grade, and Rad-score—the AUCs of the training group and validation group were 0.813 (95% CI 0.740–0.886) and 0.838 (95% CI 0.733–0.943), respectively. In the validation group, the diagnostic accuracy, sensitivity, and specificity were 0.727, 0.739, and 0.719, respectively. Conclusion Combining with radiomics based on multiphase CT images and clinical risk factors, the radiomics-clinical model constructed to predict the recurrence risk of bladder cancer within 2 years after surgery had a good performance.

The clinical significance of urinary nuclear matrix protein 22 in screening postoperative recurrence of bladder cancer

Studies on Urinary Nuclear Matrix Protein 22 Values in Patients with Transitional Cell Carcinoma of the Bladder

The Role of Nuclear Matrix Protein 22 Combined with Bladder Tumor Antigen Stat Test in Surveillance of Recurring Bladder Cancer.

Evaluation of Nuclear Matrix Protein22 (NMP22) in Urine for the Diagnosis of Bladder Transitional Cell Carcinoma

The Diagnostic and Prognostic Value of Nuclear Matrix Protein 22 in Bladder Cancer

Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma

A clinical evaluation of nuclear matrix protein 22 in urine as an adjuvant diagnostic marker for transitional cell carcinoma of the upper urinary tract

[Expression and Clinical Significance of Nuclear Matrix Protein 22 and Cytokeratin 18 in Transitional Cell Carcinoma of the Bladder].

Nuclear Matrix Protein 22 (Nmp22) Test In The Diagnosis Of Bladder Cancer: A Meta-Analysis

[Significance of Urinary Nuclear Matrix Protein 22 in Diagnosis of Transitional Cell Carcinoma of Urinary Tract].

NMP22 and BTA stat in the detection of bladder cancer

Urine Cytology and NMP22 Qualitative Assay in Diagnosis of Recurrent Bladder Transitional Cell Carcinoma

Comparison between nuclear matrix protein 22 (NMP 22) test and voided urine cytology for detection of bladder cancer

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

[The Study of Relationship Between Nuclear Metrix Protein 22 Urinary Level and the Grade and Stage of Bladder Transitional Cell Carcinoma].

Detection of Nuclear Matrix Protein 22 and Survivin Baseline Level in Patients after Radical Cystectomy.

The diagnostic efficacy and interference factors of NMP22 in urothelial carcinoma

Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images

Combined use of NMP22 and BTAstat in the screening and surveillance of bladder tumor

Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma

Nuclear matrix protein 22 in bladder cancer